Neurological complications following pediatric allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
abnormal imaging
hematopoietic stem cell transplantation
neurological complications
neurological sequelae
pediatric malignant and nonmalignant diseases
survival
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
10
2022
accepted:
01
11
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) is an efficient treatment for numerous malignant and nonmalignant conditions affecting children. This procedure can result in infectious and noninfectious neurological complications (NCs). The objective of the study is to examine the incidence, risk factors, and outcomes of NCs in pediatric patients following allogeneic HSCT. We performed a retrospective study of 746 children who underwent 943 allogeneic HSCTs in two large pediatric hospitals in Israel from January 2000 to December 2019. Of the pediatric patients 107 (14.3%) experienced 150 NCs. The median follow-up was 55 months. Noninfectious NCs were more common than infectious NCs (81.3% vs. 18.7%). Factors significantly associated with type of NC (infectious vs. noninfectious) were underlying disease (immunodeficiency vs. malignant and metabolic/hematologic disease) ( Infectious and noninfectious NCs are a significant cause of morbidity and mortality following allogeneic HSCT in children. Further research is required to better understand the risk factors for different NCs and their outcomes regarding sequelae and survival.
Sections du résumé
Background
UNASSIGNED
Allogeneic hematopoietic stem cell transplantation (HSCT) is an efficient treatment for numerous malignant and nonmalignant conditions affecting children. This procedure can result in infectious and noninfectious neurological complications (NCs).
Objective
UNASSIGNED
The objective of the study is to examine the incidence, risk factors, and outcomes of NCs in pediatric patients following allogeneic HSCT.
Methods
UNASSIGNED
We performed a retrospective study of 746 children who underwent 943 allogeneic HSCTs in two large pediatric hospitals in Israel from January 2000 to December 2019.
Results
UNASSIGNED
Of the pediatric patients 107 (14.3%) experienced 150 NCs. The median follow-up was 55 months. Noninfectious NCs were more common than infectious NCs (81.3% vs. 18.7%). Factors significantly associated with type of NC (infectious vs. noninfectious) were underlying disease (immunodeficiency vs. malignant and metabolic/hematologic disease) (
Conclusion
UNASSIGNED
Infectious and noninfectious NCs are a significant cause of morbidity and mortality following allogeneic HSCT in children. Further research is required to better understand the risk factors for different NCs and their outcomes regarding sequelae and survival.
Identifiants
pubmed: 36533248
doi: 10.3389/fped.2022.1064038
pmc: PMC9755488
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1064038Informations de copyright
© 2022 Zaidman, Shaziri, Averbuch, Even-Or, Dinur-Schejter, NaserEddin, Brooks, Shadur, Gefen and Stepensky.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2009 Jan;50(1):24-36
pubmed: 19031169
Pediatr Blood Cancer. 2020 Jun;67(6):e28224
pubmed: 32196935
Ital J Pediatr. 2010 Feb 06;36:14
pubmed: 20181110
Front Pediatr. 2021 Feb 09;8:526235
pubmed: 33634049
Bone Marrow Transplant. 2005 Jan;35(1):71-6
pubmed: 15531898
Pediatr Blood Cancer. 2008 Feb;50(2):331-6
pubmed: 17455315
Pediatr Blood Cancer. 2008 May;50(5):1018-25
pubmed: 17849473
Eur J Haematol. 2020 Dec;105(6):722-730
pubmed: 32658347
Biol Blood Marrow Transplant. 2018 Aug;24(8):1629-1642
pubmed: 29548831
Transplant Proc. 2007 Nov;39(9):2905-7
pubmed: 18022013
Neural Regen Res. 2018 Jun;13(6):945-954
pubmed: 29926815
Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82
pubmed: 25485863
Pediatr Transplant. 2014 Jun;18(4):405-11
pubmed: 24802348
Neurology. 2002 Dec 24;59(12):1895-904
pubmed: 12499480
Pediatr Transplant. 2005 Feb;9(1):62-7
pubmed: 15667614
Biol Blood Marrow Transplant. 2015 Jun;21(6):1091-8
pubmed: 25708217
J Child Neurol. 2021 Mar;36(3):169-176
pubmed: 33076756
N Engl J Med. 1999 Jul 1;341(1):14-21
pubmed: 10387937
PLoS One. 2018 Oct 16;13(10):e0204914
pubmed: 30325953
Radiographics. 2018 Jul-Aug;38(4):1223-1238
pubmed: 29995615
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2017 Mar;23(3):388-397
pubmed: 28039081
Bone Marrow Transplant. 2000 Feb;25(3):301-7
pubmed: 10673702
Pediatr Blood Cancer. 2011 Dec 15;57(7):1179-85
pubmed: 21520396
Bone Marrow Transplant. 2016 Aug;51(8):1050-61
pubmed: 27042832
Pediatr Neurol. 2020 Oct;111:78-84
pubmed: 32951667
Bone Marrow Transplant. 2004 Jul;34(2):137-42
pubmed: 15235576
Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33
pubmed: 12720215
Neurol Clin. 2010 Feb;28(1):217-34
pubmed: 19932383
Childs Nerv Syst. 2021 Dec;37(12):3753-3767
pubmed: 34546410
Cancers (Basel). 2021 Jun 21;13(12):
pubmed: 34205634
Cancer Res. 1990 Oct 1;50(19):6203-7
pubmed: 2400986
Blood Adv. 2017 Mar 28;1(9):573-576
pubmed: 29296977
Mol Clin Oncol. 2022 Jun 14;17(2):125
pubmed: 35832474
Oncogene. 2007 May 28;26(25):3644-53
pubmed: 17530018
Biol Blood Marrow Transplant. 2002;8(4):221-8
pubmed: 12014811
Biol Blood Marrow Transplant. 2019 Feb;25(2):301-306
pubmed: 30244103
BMC Cancer. 2021 Feb 10;21(1):150
pubmed: 33568096
Bone Marrow Transplant. 1991 May;7(5):363-4
pubmed: 2070145
Biol Blood Marrow Transplant. 2010 Nov;16(11):1596-602
pubmed: 20685258
J Clin Oncol. 2010 Feb 20;28(6):1011-6
pubmed: 20065176
Korean J Hematol. 2010 Sep;45(3):164-70
pubmed: 21120204
Bone Marrow Transplant. 1999 Sep;24(6):647-52
pubmed: 10490731